Brain, Vol. 114, No. 2, 775-788, 1991
© 1991 Oxford University Press
research-article |
UBIQUITIN-IMMUNOREACTIVE INTRANEURONAL INCLUSIONS IN AMYOTROPHIC LATERAL SCLEROSIS
MORPHOLOGY, DISTRIBUTION, AND SPECIFICITY
1Departments of Neurology and Neuroscience, Institute of Psychiatry London 2Midland Centre for Neurosurgery and Neurology Smethwick, West Midlands 3Department of Neuropathology The Royal London Hospital London 4Department of Neuropathology, Southampton General Hospital Southampton, UK
Correspondence to:
Correspondence to: Professor P. N. Leigh, University Department of Neurology, Institute of Psychiatry, De Crespigny Park, London SE5 8AF, UK.
Antibodies to ubiquitin have been used to search for evidence of abnormal protein degradation in amyotrophic lateral sclerosis—motor neuron disease (ALS). Anterior horn cell ubiquitin-immunoreactive (IR) inclusions were present in all of 31 ALS cases but in none of 23 neurologically normal and in only 1 of 22 neurologically abnormal controls. These inclusions, which were present in familial and sporadic ALS cases, and in cases with dementia, took the form of dense rounded or irregular ubiquitin-IR cytoplasmic inclusions (dense bodies), or loosely arranged bundles (‘skeins’) of filamentous-appearing material. The presence of ubiquitin-IR inclusions corresponded to the pattern of selective neuronal vulnerability in ALS, although inclusions in pyramidal neurons of the motor cortex were infrequent and were noted in only a minority of cases. Ubiquitin-IR inclusions were more prevalent than Bunina Bodies. The latter were present in 67% of ALS cases but were seldom labelled by antibodies to ubiquitin. Intranuronal inclusions resembling Lewy bodies were present in 23% of ALS cases and were often identified by antibodies to ubiquitin. We conclude that the presence of ubiquitin-IR inclusions in lower motor neurons represents a characteristic pathological feature of ALS in its various clinical forms. Ubiquitin-IR inclusions in ALS differ from ubiquitinated inclusions in other neuronal degenerations in that they are not readily identified by antibodies to cytoskeletal proteins. They may represent accumulations of altered or abnormal neuronal proteins resistant to degradation via the ubiquitin proteolytic pathway.
Received January 9, 1990. Revised April 17, 1990. Accepted May 7, 1990.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  I. Wegorzewska, S. Bell, N. J. Cairns, T. M. Miller, and R. H. Baloh TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration PNAS, November 3, 2009; 106(44): 18809 - 18814. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Daoud, P N Valdmanis, E Kabashi, P Dion, N Dupre, W Camu, V Meininger, and G A Rouleau Contribution of TARDBP mutations to sporadic amyotrophic lateral sclerosis J. Med. Genet., February 1, 2009; 46(2): 112 - 114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Cheroni, M. Marino, M. Tortarolo, P. Veglianese, S. De Biasi, E. Fontana, L. V. Zuccarello, C. J. Maynard, N. P. Dantuma, and C. Bendotti Functional alterations of the ubiquitin-proteasome system in motor neurons of a mouse model of familial amyotrophic lateral sclerosis Hum. Mol. Genet., January 1, 2009; 18(1): 82 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Igaz, L. K. Kwong, Y. Xu, A. C. Truax, K. Uryu, M. Neumann, C. M. Clark, L. B. Elman, B. L. Miller, M. Grossman, et al. Enrichment of C-Terminal Fragments in TAR DNA-Binding Protein-43 Cytoplasmic Inclusions in Brain but not in Spinal Cord of Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis Am. J. Pathol., July 1, 2008; 173(1): 182 - 194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Sreedharan, I. P. Blair, V. B. Tripathi, X. Hu, C. Vance, B. Rogelj, S. Ackerley, J. C. Durnall, K. L. Williams, E. Buratti, et al. TDP-43 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis Science, March 21, 2008; 319(5870): 1668 - 1672. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Spina, J. R. Murrell, E. D. Huey, E. M. Wassermann, P. Pietrini, M. A. Baraibar, A. G. Barbeito, J. C. Troncoso, R. Vidal, B. Ghetti, et al. Clinicopathologic features of frontotemporal dementia with Progranulin sequence variation Neurology, March 13, 2007; 68(11): 820 - 827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T M Polvikoski, A Murray, P S Harper, and J W Neal Familial motor neurone disease with dementia: phenotypic variation and cerebellar pathology J. Neurol. Neurosurg. Psychiatry, November 1, 2003; 74(11): 1516 - 1520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Clement, M. D. Nguyen, E. A. Roberts, M. L. Garcia, S. Boillee, M. Rule, A. P. McMahon, W. Doucette, D. Siwek, R. J. Ferrante, et al. Wild-Type Nonneuronal Cells Extend Survival of SOD1 Mutant Motor Neurons in ALS Mice Science, October 3, 2003; 302(5642): 113 - 117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Gray, M. Tsirigotis, and J. Woulfe Ubiquitin, Proteasomes, and the Aging Brain Sci. Aging Knowl. Environ., August 27, 2003; 2003(34): re6 - 6. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-i. Niwa, S. Ishigaki, N. Hishikawa, M. Yamamoto, M. Doyu, S. Murata, K. Tanaka, N. Taniguchi, and G. Sobue Dorfin Ubiquitylates Mutant SOD1 and Prevents Mutant SOD1-mediated Neurotoxicity J. Biol. Chem., September 20, 2002; 277(39): 36793 - 36798. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nagai, M. Aoki, I. Miyoshi, M. Kato, P. Pasinelli, N. Kasai, R. H. Brown Jr, and Y. Itoyama Rats Expressing Human Cytosolic Copper-Zinc Superoxide Dismutase Transgenes with Amyotrophic Lateral Sclerosis: Associated Mutations Develop Motor Neuron Disease J. Neurosci., December 1, 2001; 21(23): 9246 - 9254. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Traynor, M. B. Codd, B. Corr, C. Forde, E. Frost, and O. M. Hardiman Clinical Features of Amyotrophic Lateral Sclerosis According to the El Escorial and Airlie House Diagnostic Criteria: A Population-Based Study Arch Neurol, August 1, 2000; 57(8): 1171 - 1176. [Abstract] [Full Text] [PDF]
|
|